JP2010501519A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501519A5
JP2010501519A5 JP2009525046A JP2009525046A JP2010501519A5 JP 2010501519 A5 JP2010501519 A5 JP 2010501519A5 JP 2009525046 A JP2009525046 A JP 2009525046A JP 2009525046 A JP2009525046 A JP 2009525046A JP 2010501519 A5 JP2010501519 A5 JP 2010501519A5
Authority
JP
Japan
Prior art keywords
compound according
methyl
oxazol
azabicyclo
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525046A
Other languages
English (en)
Japanese (ja)
Other versions
JP5315244B2 (ja
JP2010501519A (ja
Filing date
Publication date
Priority claimed from GBGB0616574.0A external-priority patent/GB0616574D0/en
Application filed filed Critical
Publication of JP2010501519A publication Critical patent/JP2010501519A/ja
Publication of JP2010501519A5 publication Critical patent/JP2010501519A5/ja
Application granted granted Critical
Publication of JP5315244B2 publication Critical patent/JP5315244B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525046A 2006-08-21 2007-08-20 アザビシクロヘキサン誘導体の使用 Expired - Fee Related JP5315244B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0616574.0A GB0616574D0 (en) 2006-08-21 2006-08-21 Compounds
GB0616574.0 2006-08-21
PCT/EP2007/058636 WO2008022994A1 (en) 2006-08-21 2007-08-20 Use of azabicyclo hexane derivatives

Publications (3)

Publication Number Publication Date
JP2010501519A JP2010501519A (ja) 2010-01-21
JP2010501519A5 true JP2010501519A5 (enExample) 2010-10-07
JP5315244B2 JP5315244B2 (ja) 2013-10-16

Family

ID=37081324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525046A Expired - Fee Related JP5315244B2 (ja) 2006-08-21 2007-08-20 アザビシクロヘキサン誘導体の使用

Country Status (22)

Country Link
US (1) US20080058398A1 (enExample)
EP (1) EP2054054A1 (enExample)
JP (1) JP5315244B2 (enExample)
KR (1) KR101495362B1 (enExample)
CN (1) CN101528221B (enExample)
AR (1) AR062471A1 (enExample)
AU (1) AU2007287527B2 (enExample)
BR (1) BRPI0716454A2 (enExample)
CA (1) CA2661437A1 (enExample)
CL (1) CL2007002422A1 (enExample)
CO (1) CO6150139A2 (enExample)
CR (1) CR10638A (enExample)
EA (1) EA017917B1 (enExample)
GB (1) GB0616574D0 (enExample)
IL (1) IL196976A0 (enExample)
MA (1) MA30672B1 (enExample)
MX (1) MX2009001941A (enExample)
NO (1) NO20090834L (enExample)
PE (1) PE20080609A1 (enExample)
TW (1) TW200825074A (enExample)
WO (1) WO2008022994A1 (enExample)
ZA (1) ZA200900886B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
ATE484502T1 (de) * 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
JP5237807B2 (ja) * 2005-08-22 2013-07-17 グラクソ グループ リミテッド ドーパミンd3受容体の調節因子としてのトリアゾール誘導体
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
WO2007113260A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
EP2167083B1 (en) * 2007-06-06 2015-10-28 Euthymics Bioscience, Inc. 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260941B2 (ja) * 1998-11-09 2009-04-30 株式会社片山製薬所 アゼチジン−3−オール
DE60022742D1 (de) * 1999-03-15 2006-02-02 Novo Nordisk As Salz des (2r,3r,4r)-3,4-dihydroxy-2-hydroxmethylpyrrolidins
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
PE20051173A1 (es) * 2004-02-23 2006-02-14 Glaxo Group Ltd Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
SE526837C2 (sv) 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
MXPA06015112A (es) * 2004-06-30 2007-02-08 Lilly Co Eli D-tartrato de 1-(indol-6-carbonil-d-fenilglicinil)-4-(1-metilpiperidin-4-il) piperazina.
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Similar Documents

Publication Publication Date Title
JP2010501519A5 (enExample)
JP2013503134A5 (enExample)
JP2018115191A5 (enExample)
JP2022049005A5 (enExample)
EP3029039B1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
JP2020511467A5 (enExample)
TWI720272B (zh) 雜芳基苯氧基苯甲醯胺kappa類鴉片配體
JP2014526549A5 (enExample)
JP2014518266A5 (enExample)
JP2011505356A5 (enExample)
US10100032B2 (en) Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2014524442A5 (enExample)
JP2012067131A5 (enExample)
RU2016123382A (ru) Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
JP2009506014A5 (enExample)
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
HK1225719A1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl) benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
CN102066376B (zh) 马来酸欧维特的无水晶型
JP2014524476A5 (enExample)
CN105324375A (zh) 盐酸尼洛替尼的多晶型形式
JP2013514974A5 (enExample)
RU2012136148A (ru) Новая кристаллическая форма производного циклопропилбензамида
JP2017525717A5 (enExample)
JP2013520412A5 (enExample)
RU2451016C2 (ru) Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида